RxDoctor Payments Data

Roy Gandolfi, MD

Internal Medicine · West Valley City, UTNPI 1740211101

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Gen-probe, Inc. at 49.5% of the total. Reporting peaked in 2024 at $4,259 and has fallen 91.2% since, to $375 in 2025. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,277in general payments, 2019–2025

Across 273 payments — averaging $44.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gen-probe, Inc.$6K
  • Medtronic$834
  • Hologic Sales And Service, LLC$612
  • Boehringer Ingelheim$573
  • Gen-probe Sales & Service, Inc.$533
  • Amgen$441
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$5,75047%
  • Travel & lodging$1,99616%
  • Food & beverage$4,49137%
  • Education$210%
  • Other$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,277 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$162,575
Medicare patients
292
Services billed
6,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$207,783
JardianceEmpagliflozin143$151,917
OzempicSemaglutide73$98,101
XareltoRivaroxaban66$60,768
MounjaroTirzepatide57$58,439
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog46$37,887
TrulicityDulaglutide18$19,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,730
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$16,251
FarxigaDapagliflozin Propanediol17$13,559
Gabapentin322$10,914
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$10,253
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$9,615
Omeprazole504$9,241
Humalog Kwikpen U-100Insulin Lispro32$9,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$327$207,783242 claims
Boehringer IngelheimJardiance, Stiolto Respimat$573$162,171165 claims
Novo NordiskOzempic$231$98,10173 claims
Lilly USA, LLCMounjaro, Trulicity$148$78,12575 claims
Johnson & JohnsonXarelto$233$60,76866 claims
GSKTrelegy Ellipta, Anoro Ellipta$293$22,44936 claims
AstraZenecaFarxiga$197$13,55917 claims
AbbVieLinzess, Synthroid$89$10,23856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.

Other internal medicine in West Valley City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →